Guardant Health
Guardant Health's revenue rose 32.9% to $982 million in fiscal 2025. Its operating margin was −44.5%, up from −60.0% a year earlier. Free cash flow was −$233 million. It paid out $45 million in dividends and buybacks. The diluted share count rose 2.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Guardant Health does
Guardant Health makes blood and tissue tests for cancer, run in its own laboratories. For patients with advanced cancer, its Guardant360 tests look for gene changes in a tumor to help doctors choose a treatment. Its Guardant Reveal test watches for cancer coming back after treatment. Its Shield blood test screens adults 45 and older for colorectal cancer, and the 10-K says it was the first blood test the FDA approved for that purpose.
The company had total revenue of $982.0 million in 2025, and it still lost money. Oncology tests for doctors and hospitals brought in $683.6 million. Work for drug makers, who use its tests and data in clinical trials, brought in $210.1 million. Shield screening brought in $79.7 million. It names Foundation Medicine among its competitors in tests used to choose a therapy.
At the end of 2025 Guardant had 2,506 employees, most of them in the United States. Medicare paid for more than a tenth of its revenue in each of the past three years.
Its biggest risks, as it describes them
- It has lost money since it began and may not earn enough revenue to become profitable.
- Insurers and Medicare may not cover its tests or pay enough for them.
- Stricter FDA rules for lab-developed tests could add costly requirements for several of its tests.
- Rivals entering liquid biopsy and cancer screening could slow the adoption of its tests.
- Its reliance on a few suppliers, couriers and its main laboratory to process samples.
Income statement
Guardant Health lost money in fiscal 2025: a net loss of $416 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 933 | 1,011 | 1,169 | 840 | 1,202 |
| Debt incl. finance leases | 1,135 | 1,137 | 1,140 | 1,142 | 1,504 |
| Net debt (negative means net cash) | 202 | 126 | −29 | 302 | 302 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.8x | — | 7.2x | — | — |
| Interest coverage | −159.5x | −211.2x | −219.1x | −171.9x | −112.2x |
| Current ratio | 5.7x | 6.2x | 6.5x | 4.7x | 4.8x |
| Quick ratio | 5.6x | 5.9x | 6.2x | 4.4x | 4.6x |
Cash flow
Projections
Project Guardant Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Guardant Health says to expect
- Full year 2026: revenue
Guardant Health now expects full year 2026 revenue to be in the range of $1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025.
- Full year 2026: screening revenue and Shield volume
Screening revenue is now expected to be in the range of $233 to $238 million, driven by Shield volume of 285,000 to 290,000 tests.
- Full year 2026: non-GAAP gross margin
Guardant Health now expects full year 2026 non-GAAP gross margin to be 65%, compared to prior guidance of 64% to 65%.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $78,456 of Guardant Health shares on the open market, and 15 insiders sold $173.5 million, $81.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Terilyn J. MonroeChief People Officer | Sold plan | 3,842 | $142.41 | $547,149 | Form 4 |
| Nov 16, 2026 | Musa TariqDirector | Sold plan | 116 | $149.56 | $17,349 | Form 4 |
| Nov 16, 2026 | Alex M Azar IIDirector | Sold plan | 69 | $149.56 | $10,320 | Form 4 |
| Sep 16, 2026 | Steve E. KrognesDirector | Sold | 6,674 | $175.74 | $1.2 million | Form 4 |
| Sep 16, 2026 | Alex M Azar IIDirector | Sold plan | 826 | $175.00 | $144,550 | Form 4 |
| Sep 16, 2026 | Musa TariqDirector | Sold plan | 116 | $175.00 | $20,300 | Form 4 |
| Sep 15, 2026 | Darya ChudovaChief Technology Officer | Sold | 7,738 | $178.00 | $1.4 million | Form 4 |
| Sep 11, 2026 | Kumud KaliaChief Information Officer | Sold | 4,000 | $158.05 | $632,200 | Form 4 |
| Aug 21, 2026 | AmirAli TalasazCo-Chief Executive Officer, Director | Sold | 37,500 | $169.16 | $6.3 million | Form 4 |
| Aug 17, 2026 | Musa TariqDirector | Sold plan | 116 | $156.45 | $18,148 | Form 4 |
| Aug 12, 2026 | Terilyn J. MonroeChief People Officer | Sold | 46,300 | $165.12 | $7.6 million | Form 4 |
| Aug 10, 2026 | Chris FreemanChief Commercial Officer | Sold | 63,605 | $169.58 | $10.8 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 4 of 9 | 4 of 9 |
| Rule of 40 | −35.8% | −6.2% | 9.2% |
| Altman Z'' | −1.74 | −4.09 | −2.57 |
| Accruals ratio | −9.1% | −12.0% | −13.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 3 of 8 | 4 of 9 | 4 of 9 |
Compare
Put Guardant Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Guardant Health | FY25 | 32.9% | −44.5% | −23.7% | −188.8% | — | 4 | |
| InnovAge | FY26 | 15.9% | 0.3% | 5.1% | 0.7% | −3.3x | 6 | Compare |
| CorVel | FY26 | 7.0% | — | 11.5% | — | — | — | Compare |
| Pennant Group | FY25 | 36.3% | 5.5% | 3.8% | 9.3% | 2.6x | 5 | Compare |
| Sotera Health | FY25 | 5.7% | — | 12.8% | 6.7% | — | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 25 | 50 | 91 | 214 | 287 | 374 | 450 | 564 | 739 | 982 |
| Revenue growth | — | 97.4% | 81.8% | 136.5% | 33.8% | 30.3% | 20.3% | 25.4% | 31.0% | 32.9% |
| Gross profit | — | — | — | — | — | — | — | 337 | 449 | 633 |
| Research and development | 11 | 26 | 51 | 86 | 150 | 263 | 374 | 367 | 348 | 364 |
| Operating income | −44 | −77 | −93 | −82 | −255 | −411 | −544 | −565 | −444 | −437 |
| Net income | −46 | −83 | −85 | −76 | −246 | −385 | −655 | −479 | −436 | −416 |
| Diluted EPS (US$) | −3.53 | −7.07 | −2.80 | −0.84 | −2.60 | −4.00 | −6.41 | −4.28 | −3.56 | −3.32 |
| Diluted shares (millions) | 13 | 13 | 30 | 91 | 98 | 101 | 102 | 112 | 123 | 125 |
| Cash flow | ||||||||||
| Cash from operations | −37 | −72 | −72 | −47 | −104 | −209 | −310 | −325 | −240 | −185 |
| Capital expenditure | 2 | 7 | 20 | 19 | 36 | 75 | 78 | 20 | 35 | 48 |
| Free cash flow | −38 | −79 | −92 | −66 | −140 | −284 | −387 | −345 | −275 | −233 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45 |
| Acquisitions | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 59 |
| Stock-based compensation | 2 | 4 | 7 | 17 | 144 | 151 | 95 | 91 | 140 | 166 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 34 | 221 | 419 | 523 | 1,795 | 933 | 1,011 | 1,169 | 840 | 1,202 |
| Debt incl. finance leases | — | — | — | 0 | 806 | 1,135 | 1,137 | 1,140 | 1,142 | 1,504 |
| Total assets | — | 343 | 587 | 962 | 2,272 | 2,204 | 1,610 | 1,786 | 1,486 | 2,014 |
| Total liabilities | — | 34 | 62 | 114 | 916 | 1,560 | 1,550 | 1,628 | 1,625 | 2,113 |
| Shareholders' equity | 80 | 309 | 483 | 798 | 1,298 | 645 | 60 | 159 | −140 | −99 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | 59.7% | 60.8% | 64.5% |
| Operating margin | −173.7% | −153.7% | −102.5% | −38.4% | −88.9% | −110.0% | −121.1% | −100.1% | −60.0% | −44.5% |
| Net margin | −182.7% | −167.0% | −93.8% | −35.3% | −85.9% | −103.0% | −145.6% | −85.0% | −59.0% | −42.4% |
| Free cash flow margin | −152.4% | −158.3% | −101.9% | −30.7% | −48.9% | −76.0% | −86.1% | −61.3% | −37.2% | −23.7% |
| Rule of 40 (growth + FCF margin) | — | −60.9% | −20.1% | 105.8% | −15.1% | −45.7% | −65.8% | −35.8% | −6.2% | 9.2% |
| Return on capital | — | — | — | — | −68.8% | −56.1% | −83.2% | — | — | −188.8% |
| Return on equity | — | — | −21.5% | −11.8% | −23.5% | −39.6% | −185.7% | −438.1% | — | — |
| Return on assets | — | — | −18.3% | −9.8% | −15.2% | −17.2% | −34.3% | −28.2% | −26.7% | −23.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |